164 related articles for article (PubMed ID: 10565232)
1. [Factor IX inhibitor in hemophilia B presented with anaphylactoid symptoms: report of 3 cases].
Taketani T; Hanada R; Kawaguchi H; Ida K; Yamamoto K
Rinsho Ketsueki; 1999 Oct; 40(10):1124-6. PubMed ID: 10565232
[TBL] [Abstract][Full Text] [Related]
2. Achievement of immune tolerance in a patient with haemophilia B and inhibitory antibodies, complicated by an anaphylactoid reaction.
Curry NS; Misbah SA; Giangrande PL; Keeling DM
Haemophilia; 2007 May; 13(3):328-30. PubMed ID: 17498084
[TBL] [Abstract][Full Text] [Related]
3. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.
Alexander S; Hopewell S; Hunter S; Chouksey A
J Pediatr Hematol Oncol; 2008 Jan; 30(1):93-5. PubMed ID: 18176193
[TBL] [Abstract][Full Text] [Related]
4. Incidence of factor IX inhibitor development in severe haemophilia B patients treated with only one brand of high purity plasma derived factor IX concentrate.
Parquet A; Laurian Y; Rothschild C; Navarro R; Guérois C; Gay V; Durin A; Peynet J; Sultan Y
Thromb Haemost; 1999 Oct; 82(4):1247-9. PubMed ID: 10544907
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to factor IX.
Warrier I
Haematologica; 2000 Oct; 85(10 Suppl):31-3; discussion 33-4. PubMed ID: 11187867
[No Abstract] [Full Text] [Related]
6. Failure of immunosuppression in a severe haemophilia B patient with specific antibody.
Allain JP; Frommel D
Thromb Haemost; 1976 Aug; 36(1):86-9. PubMed ID: 1036830
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors in young boys with haemophilia.
Lusher JM
Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
[TBL] [Abstract][Full Text] [Related]
8. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
Barnes C; Davis A; Furmedge J; Egan B; Donnan L; Monagle P
Haemophilia; 2010 Sep; 16(5):840-1. PubMed ID: 20546030
[No Abstract] [Full Text] [Related]
9. Safety and efficacy of monoclonal antibody purified factor IX concentrate in previously untreated patients with hemophilia B.
Shapiro AD; Ragni MV; Lusher JM; Culbert S; Koerper MA; Bergman GE; Hannan MM
Thromb Haemost; 1996 Jan; 75(1):30-5. PubMed ID: 8713776
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of OCTANINE F in children with haemophilia B.
Klukowska A; Laguna P; Svirin P; Shiller E; Vdovin V
Haemophilia; 2008 May; 14(3):531-8. PubMed ID: 18355266
[TBL] [Abstract][Full Text] [Related]
11. Factor IX alloantibodies shorten the bovine thromboplastin coagulation time of normal human plasma.
Orstavik KH
Thromb Haemost; 1981 Dec; 46(4):684-6. PubMed ID: 7330818
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
Mathias M; Khair K; Hann I; Liesner R
Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
[TBL] [Abstract][Full Text] [Related]
13. Involvement of the IgE-basophil system and mild complement activation in haemophilia B with anti-factor IX neutralizing antibodies and anaphylaxis.
Cugno M; Mancuso ME; Tedeschi A; Santagostino E; Lorini M; Carbonelli V; Peyvandi F; Mannucci PM
Haemophilia; 2017 Jul; 23(4):e348-e353. PubMed ID: 28594432
[TBL] [Abstract][Full Text] [Related]
14. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
Chuansumrit A; Moonsup Y; Sirachainan N; Benjaponpitak S; Suebsangad A; Wongwerawattanakoon P
Blood Coagul Fibrinolysis; 2008 Apr; 19(3):208-11. PubMed ID: 18388500
[TBL] [Abstract][Full Text] [Related]
15. Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk.
Thorland EC; Drost JB; Lusher JM; Warrier I; Shapiro A; Koerper MA; Dimichele D; Westman J; Key NS; Sommer SS
Haemophilia; 1999 Mar; 5(2):101-5. PubMed ID: 10215957
[TBL] [Abstract][Full Text] [Related]
16. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
[TBL] [Abstract][Full Text] [Related]
17. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
18. A simple inhibitor screen is more sensitive than a Bethesda assay in monitoring for the development of inhibitors in haemophilia A and B.
Keeling D; Beavis J; Sukhu K
Br J Haematol; 2005 Mar; 128(6):885. PubMed ID: 15755295
[No Abstract] [Full Text] [Related]
19. Combined factor VIII and IX inhibitors in a non-haemophilic patient: successful treatment with immunosuppressive drugs.
Carmassi F; Giannarelli C; De Giorgi A; De Negri F
Haemophilia; 2007 Jan; 13(1):106-7. PubMed ID: 17212735
[TBL] [Abstract][Full Text] [Related]
20. [The successful use of FEIBA for treatment of intracranial hemorrhage in a patient of hemophilia B with inhibitor].
Taki M; Inagaki M; Tomita Y; Miura T; Saito N; Meguro T; Yamada K
Rinsho Ketsueki; 1985 Aug; 26(8):1300-5. PubMed ID: 3877831
[No Abstract] [Full Text] [Related]
[Next] [New Search]
